AIM2 upregulation was found to predict a favorable prognosis in colorectal cancer [7, 8], gastric cancer [9] and osteosarcoma [10], but associated with cancer progression, e.g. tumor growth, metastasis and immunosuppression, in non-small cell lung cancer [13, 14], melanoma [15], triple-negative breast cancer [16] and renal cell carcinoma [17]. Here, AIM2 is linked to gastric cancer.